T-group (topology)
304.28.1 Multidrug efflux transporter AcrB pore domain
Ligands and drugs
3,549
Member domains
566
with ligand contacts (≤ 4 Å)
15.9% of members
449
with DrugDomain annotations
12.7% of members
279
with a DrugBank compound
7.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 304.28.1 belongs to X-group 304 Alpha-beta plaits, which binds 8.8 ligand superclasses per 20 proteins, broader than 75% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00199 | ERY | Erythromycin | 43 |
| DB01017 | MIY | Minocycline | 30 |
| DB00141 | NAG | N-Acetylglucosamine | 25 |
| DB03279 | LMU | Dodecyl-Alpha-D-Maltoside | 15 |
| DB17031 | ET | Homidium | 11 |
| DB00997 | DM2 | Doxorubicin | 10 |
| DB02703 | FUA | Fusidic acid | 7 |
| DB01045 | RFP | Rifampin | 6 |
| DB00163 | VIV | Vitamin E | 4 |
| DB00537 | CPF | Ciprofloxacin | 4 |
| DB00615 | RBT | Rifabutin | 4 |
| DB03825 | RHQ | Rhodamine 6G | 4 |
| DB04729 | LLL | Gentamicin C1a | 4 |
| DB08437 | PUY | Puromycin | 4 |
| DB00973 | H56 | Ezetimibe | 3 |
| DB00254 | DXT | Doxycycline | 2 |
| DB00446 | CLM | Chloramphenicol | 2 |
| DB00607 | NFN | Nafcillin | 2 |
| DB01137 | LFX | Levofloxacin | 2 |
| DB03619 | DXC | Deoxycholic acid | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 46 |
| ERY | ERYTHROMYCIN A | 39 |
| MIY | (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE | 25 |
| CLR | CHOLESTEROL | 14 |
| 3YI | (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate | 12 |
| ET | ETHIDIUM | 12 |
| L6T | alpha-D-glucopyranosyl 6-O-dodecyl-alpha-D-glucopyranoside | 12 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 11 |
| ZNmetal | ZINC ION | 10 |
| DM2 | DOXORUBICIN | 9 |
| P9D | [{2-[({[(3R)-1-{8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-4H-pyrido[1,2-a]pyrimidin-2-yl}piperidin-3-yl]oxy}carbonyl)amino]ethyl}(dimethyl)ammonio]acetate | 9 |
| 5QF | 6-[2-(3,4-dimethoxyphenyl)ethylsulfanyl]-8-[4-(2-methoxyethyl)piperazin-1-yl]-3,3-dimethyl-1,4-dihydropyrano[3,4-c]pyridine-5-carbonitrile | 8 |
| AV0 | Lauryl Maltose Neopentyl Glycol | 8 |
| CUmetal | COPPER (II) ION | 8 |
| CU1metal | COPPER (I) ION | 8 |
| FUA | FUSIDIC ACID | 8 |
| D10 | DECANE | 7 |
| LMU | DODECYL-ALPHA-D-MALTOSIDE | 7 |
| WQW | 3-chloranyl-2,6-di(piperazin-4-ium-1-yl)quinoline | 6 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 6 |